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Abstract
Background:  Plasmodium vivax malaria accounts for approximately 60% of malaria cases in
Kolkata, India. There has been limited information on the genotypic polymorphism of P. vivax in this
malaria endemic area. Three highly polymorphic and single copy genes were selected for a study of
genetic diversity in Kolkata strains.
Methods: Blood from 151 patients with P. vivax infection diagnosed in Kolkata between April 2003
and September 2004 was genotyped at three polymorphic loci: the P. vivax circumsporozoite
protein (pvcs), the merozoite surface protein 1 (pvmsp1) and the merozoite surface protein 3-alpha
(pvmsp3-alpha).
Results: Analysis of these three genetic markers revealed that P. vivax populations in Kolkata are
highly diverse. A large number of distinguishable alleles were found from three genetic markers: 11
for pvcs, 35 for pvmsp1 and 37 for pvmsp3-alpha. These were, in general, randomly distributed
amongst the isolates. Among the 151 isolates, 142 unique genotypes were detected the
commonest genotype at a frequency of less than 2% (3/151). The overall rate of mixed genotype
infections was 10.6%.
Conclusion: These results indicate that the P. vivax parasite population is highly diverse in Kolkata,
despite the low level of transmission. The genotyping protocols used in this study may be useful for
differentiating re-infection from relapse and recrudescence in studies assessing of malarial drug
efficacy in vivax malaria.
Background
Malaria remains one of the most important communica-
ble diseases in the world. Despite enormous control
efforts over many decades malaria is still a significant
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health problem. It is estimated that around 300–500 mil-
lion cases occur each year with one to three million
deaths. The problem is compounded by multiple drug
resistance in Plasmodium falciparum and chloroquine
resistance in Plasmodium vivax [1]. The global burden of
malaria due to P. vivax is 70–80 million cases annually.
Vivax malaria is usually a non-lethal infection but its pro-
longed and recurrent infection can have major deleterious
effects on personal well-being, growth and on the eco-
nomic performance at the individual, family, community
and national levels [2]. The recent emergence of chloro-
quine-resistant strains is of great concern [3-5].
P. vivax causes about 60–65% of all malaria infections in
India [6,7,42]. The frequency of relapse after a standard
course of chloroquine and primaquine treatment is 23–
40% depending on the duration of follow-up in India
[7,36]. P. vivax and P. falciparum are prevalent in all age
groups but their prevalence is highly seasonal and differs
between the species; longitudinal studies in India show a
winter peak for P. falciparum and a summer peak for P.
vivax [7,8]. Chloroquine appears to remain an effective
drug in the treatment of P. vivax malaria in Kolkata [6].
The majority of studies on the genetic structure of Plasmo-
dium have focused on P. falciparum, using polymorphic
markers such as the merozoite surface protein-1(msp-1), -
2 (msp-2), glutamate-rich protein (glurp) [9,14]. A similar
approach has been adopted for P. vivax but it has been less
well-studied at the molecular level than P. falciparum [18].
Three polymorphic P. vivax genes have been widely used
for molecular epidemiological studies. The pvcs gene has a
central repeat domain that varies in sequence and number
of repeat units [10,41]. Two major types, VK 210 and
VK247, have a worldwide distribution and four subtypes
from VK210 and two subtypes from VK 247 can be differ-
entiated by restricted enzyme digestion to show polymor-
phisms in both the pre- and post- repeat region [28]. The
pvmsp1 gene has been used to determine whether an infec-
tion is a result of a new infection or a relapse [11] and
used to genotype isolates of different strains from differ-
ent geographical regions [12,13,15-17]. The polymorphic
pvmsp3-alpha gene was also studied by polymerase chain
reaction-restriction fragment length polymorphism (PCR-
RFLP) analysis [19,20]. The pvmsp3-alpha gene encodes a
merozoite surface protein with an alanine-rich central
domain that is predicted to form a coiled-coil tertiary
structure [21]. There is added interest in the pvmsp3 anti-
gen family as immunogens and vaccine candidates. Use of
the pvmsp3-alpha gene as genetic marker has been recently
validated [19,20,24,30,39,40]. Other genetic markers
used for P. vivax are the apical membrane antigen 1 (Ama-
1), gametocyte antigen 1 (gam1) and msp3-beta. The
PvAma-1 is a protein essential for erythrocyte invasion,
which shows limited sequence polymorphism [26,34].
The potential of pvgam1 as a molecular marker for geno-
typing is compromised by artifacts associated with ampli-
fication of this region [29]. The pvmsp3 - b e t a  g e n e  i s  a
member of a family of related merozoite surface proteins
containing a central alanine-rich central region with sig-
nificant genetic diversity [22,30]. Despite this high level of
sequence diversity certain physical properties of the
encoded protein are maintained, particularly the ability to
form coiled-coil tertiary structure [22], which may limit
genetic studies.
Studies using single or combined pvcs, pvmsp1 and pvmsp3-
alpha genotyping have assessed the genetic diversity of P.
vivax isolates from various regions. A study on pvcs identi-
fied that the VK247 genotype was widely distributed and
was the predominant form in Thai and Papua New
Guinea isolates but its prevalence was much lower in Mex-
ico [23]. Another study, by contrast, revealed that the
VK210 type in dimorphic pvcs  gene was found in the
majority of the parasites in Thai strains [24,10]. A recent
single gene study of pvmsp3-alpha revealed that it was
highly polymorphic, and that three major types of the
pvmsp3-alpha locus could be distinguished [32,39]. More-
over earlier studies revealed a high prevalence of multiple
genotype infection as determined by pvmsp3-alpha [19]
and pvcs genotyping [18]. Recently a combined pvcs and
pvmsp1 study showed a lower rate of multiple genotype
infections than an earlier study and high polymorphism
in Thai strains [28]. In hyperendemic areas, intragenic
recombination and high genetic diversity have been
reported in pvmsp1 and pvmsp3-alpha [16,20,39]. Even in
hypoendemic areas, such as Thailand and Brazil [11],
pvmsp1 and pvmsp3-alpha display high levels of diversity
[24]. By contrast, relatively low genetic diversity of pvmsp1
has been detected in the re-emerging vivax malaria focus
in Korea [31]. Little is known about the genetic diversity
among parasite populations in India, where most vivax
malaria in the world occurs. Earlier studies carried out
using isoenzyme typing was consistent with the random
mating nature of vivax malaria isolates in India [27].
Recent studies on the polymorphism of pvcs, pvgam1 and
pvmsp3 alpha in Indian isolates have revealed two types of
pvcs and nine size variations of pvgam1 and high polymor-
phism in the pvmsp3 alpha gene [37]. Therefore, the
highly polymorphic, single-copy, unlinked genes, pvcs,
pvmsp1 and pvmsp3-alpha were selected for this study of
genetic diversity of P. vivax in Kolkata.
Methods
Blood samples
Venous blood samples were collected from patients with
symptomatic  P.  vivax  malaria (n = 151) attending the
malaria clinic in the Calcutta School of Tropical Medicine,
India, between April 2003 and September 2004. All
patients gave fully informed consent to participate in thisMalaria Journal 2006, 5:71 http://www.malariajournal.com/content/5/1/71
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study which was approved by the Ethics committee of the
Faculty of Tropical Medicine, Mahidol University and also
permitted by the Calcutta School of Tropical Medicine.
The diagnosis of vivax malaria was made by examination
of thin and thick blood smear. Patients with pregnancy,
G6PD deficiency and any underlying haemolytic diseases,
and aged below three years old were excluded. Chloro-
quine (25 mg base/kg) either alone or in conjunction with
a five- or fourteen-day regimen of primaquine (15 mg
base/day), was given to the 151 patients; primaquine was
given only to non-G6PD deficiency cases. G6PD tests were
done at the Centre for Tropical Medicine and Parasitol-
ogy. Blood samples were collected in EDTA tubes from
patients with confirmed P. vivax infection and were stored
at -20°C until DNA extraction.
DNA template preparation
DNA was purified from 1 ml of infected venous blood
using a commercially available DNA extraction kit (QIA-
GEN, Germany) according to a procedure described previ-
ously [28].
Amplification protocol
A nested PCR approach was adopted following previously
described procedures [28,19]. All amplification reactions
were carried out in a total volume of 20 μL in the presence
of 10 mM Tris-HCl, pH8.3, 50 mM KCl, 250 nM of each
oligonucleotide primer, 125 μM of each of the four dNTPs
and 0.4 units of ampli-Taq polymerase (Invitrogen, USA).
Primary amplification reactions were initiated with 1 μL
of the template genomic DNA prepared from the blood
samples, and the 1 μL of the product of these reactions
was used to initiate the secondary amplification reaction.
The PCR parameters were as follows: an initial denatura-
tion step at 95°C for five minutes preceded the cycles of
annealing at a temperature defined for each primer pair
for two minutes, extension at 72°C for two minutes, and
denaturation at 94°C for one minute. After a final anneal-
ing step followed by five minutes of extension, the reac-
tion was terminated by reducing products temperature to
25°C. PCR products were stored at 4°C until analysis.
Analysis of the amplification product
The DNA fragments obtained from PCR were analyzed by
electrophoresis in agarose gels. For direct analysis of the
fragments, 10 μL of the amplified PCR product were
applied to 1.5% horizontal agarose gels for pvcs, 2.0% for
the second fragment of pvmsp1 and 1.0% for pvmsp3-alpha
at 120 volts. The size of the amplified DNA was estimated
by comparing its mobility to a molecular weight marker.
A 100 bp DNA ladder was used as a molecular weight
marker in gel electrophoresis for pvcs and the second frag-
ment of pvmsp1 but a 1 kb DNA ladder (Life and Technol-
ogies, U.S.A) was used as a molecular weight marker in the
gel electrophoresis for pvmsp3-alpha as this contains a
1900 bp DNA fragment. For restriction fragment length
polymorphism analysis of the PCR products (PCR-RFLP),
10 μL of the amplified PCR product were first digested
with a restriction enzyme (New England Biolabs Inc, UK)
for three hours in a total volume of 20 μL, before applying
to 1.5% or 1.8% agarose gels. Electrophoresis was per-
formed in TBE buffer, and the DNA was visualized on an
ultraviolet transilluminator following ethidium bromide
staining. For the purpose of this study, the frequency of an
allele is calculated simply as its percentage of the total of
all alleles detected among the isolates examined.
Results
Genotyping of pvcs
Amplification of the fragment containing the pvcs gene
was attempted for blood samples obtained from patients.
After two rounds of PCR, bands of 680–740 bp were
amplified. This nested PCR generated three product size
variants (Table 1). All the allelic variants were ordered in
decreasing sizes of base pairs and coded alphabetically,
starting a to c. The frequencies of type a (740 bp), type b
(710 bp) and type c (680 bp) were 28%, 65% and 7%,
respectively (Figure 1). The most common allele was type
b (65%; 97/151). Two cases of type a were mixed with
type b. There were two types of repeat region in the pvcs
gene: the VK210 type of repeat unit coding for Gly-Asp-
Arg-Ala-Asp/Ala-Gly-Gln-Pro-Ala [41], and the VK247
type coding for repeats of Ala-Asn-Gly-Ala-Gly-Asn-Gln-
Pro-Gly [10]. VK210 and VK247 were distinguished by
digestion with the restriction enzymes, Alu1 and BstN1. In
151 samples 150 isolates were VK210 type and only one
isolate was VK247 (Table 1).
PCR products were digested by ScrF1, which recognizes
insertion on 5'CC/NGG3' restriction site in the pre
repeated region and by Bbs1, which cuts the DNA on
5'GAAGACNN/NN3' site in post repeated region. There-
fore, there are four possible combinations in the VK210
type (no/in, no/no, in/in and in/no) but in VK247 type
Table 1: Size and RFLP patterns and populations of pvcs alleles (n 
= 151).
Alleles Size variation Pre/Post patterns n (%)
1. VK247 a in 1 (0.66)
2. VK210 a in/in 2 (1.32%)
3. VK210 a no/in 26 (17.2%)
4. VK210 a no/no 16 (10.6%)
5. VK210 a+b no/in 2 (1.32%)
6. VK210 b in/in 4 (2.64%)
7. VK210 b no/in 48 (31.7%)
8. VK210 b no/no 45 (29.8%)
9. VK210 c in/in 1 (0.66%)
10. VK210 c no/in 2 (1.32%)
11. VK210 c no/no 5 (3.3%)Malaria Journal 2006, 5:71 http://www.malariajournal.com/content/5/1/71
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two types were possible (in or no). Three variants were
found in the samples (no/no, no/in, and in/in) and two
of them (no/no and no/in) were predominant in the
Kolkata strains (Figure 1). The frequencies of these were
43.7% for no/no and 51% for no/in respectively. Eleven
alleles of pvcs (combinations of size variation and inser-
tion presence/absence) were found in 151 isolates, and
these were randomly distributed (Figure 2).
Genotyping of pvmsp1
The second fragment of pvmsp1 generated 1087–1150 bp
from 151 samples.
Analysis on agarose gels revealed two different sizes,
labeled a and b. Despite the lack of variation in the size of
the amplification products, RFLP analysis with Alu1 and
Mnl1 restriction enzymes revealed substantial diversity at
the nucleotide level. The RFLP patterns of different iso-
lates showed variation in size. Digestion with either Alu1
or Mnl1 yielded fragment sizes that were highly polymor-
phic. From the 151 samples 8 different Alu1 patterns and
5 different Mnl1 patterns were observed (Figure 3). When
data from both analyses were combined, 35 alleles of the
second fragment of pvmsp1 could be differentiated (Table
2).
The frequency distribution of the 35 alleles of the second
fragment of pvmsp1 is shown in Figure 4. It was found that
alleles 1 (a a1 m1) and 18 (b a1 m1), alleles 4 (a a2 m2)
and 28 (b a5 m4) were particularly predominant (20 and
26, 17 and 16 respectively among 151 samples [13.2,
17.2, 11.2 and 10.6% respectively]). The remaining iso-
lates were randomly distributed between the other vari-
ants.
Genotyping of pvmsp3-alpha
Amplification products showed a major size polymor-
phism with three different variants labelled a, b and c
(1900-1100 bp). These were predominantly of a  size
(102/151 [67.5%]) (Figure 5). The frequencies of type a
(1900 bp), type b (1500 bp) and type c (1100 bp) were
67.5%, 12.5% and 20% respectively. RFLP analysis with
Alu1 and Hha1 restriction enzymes revealed substantial
diversity at nucleotide level. Digestion with these enzymes
yielded fragment sizes that were highly polymorphic. The
sum of the fragment sizes did not always equal the size of
the intact PCR product, indicating non-resolvable varia-
tion in size of the uncut amplification products but never
more than the total size, thereby indicating a number of
mixed genotypes. From the 151 samples, five different
Alu1 patterns and five different Hha1 RFLP patterns were
The predominant two variants (no/no and no/in) of VK210 type of pvcs gene observed in the 150 isolates from Kolkata, India Figure 1
The predominant two variants (no/no and no/in) of VK210 type of pvcs gene observed in the 150 isolates from Kolkata, India. 
M is a 100 bp DNA ladder. Co and Pr and Po stand for control (nested PCR product), pre-repeat region digested by ScrF1 
enzyme and post-repeat region digested by Bbs1 enzyme, respectively. The three size variants a, b and c are 740, 710 and 680 
bp, respectively.Malaria Journal 2006, 5:71 http://www.malariajournal.com/content/5/1/71
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observed. When data from both analyses were combined,
37 alleles of pvmsp3-alphacould be differentiated (Table
3). The frequency distribution of the 37 alleles of pvmsp3-
alpha alleles in 151 isolates is shown in Figure 6. Allele 1
(a al1 h1) was particularly dominant (22/151 [14.5%])
and the others were randomly distributed.
A) Dominant alleles by Alu1 restriction enzyme digestion of the second fragment of pvmsp1 gene Figure 3
A) Dominant alleles by Alu1 restriction enzyme digestion of the second fragment of pvmsp1 gene. B) Dominant alleles by Mnl1 
restriction enzyme digestion of the second fragment of pvmsp1 gene. M is a DNA marker in 100 bp steps.
Allele frequency distribution of pvcs observed in the 151 Kolkata isolates Figure 2
Allele frequency distribution of pvcs observed in the 151 Kolkata isolates.Malaria Journal 2006, 5:71 http://www.malariajournal.com/content/5/1/71
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Analysis of three genes genotyping
The results showed marked genetic diversity in the Kolk-
ata strains with 11 alleles for pvcs, 35 alleles of the second
fragment of pvmsp1, and 37 alleles of pvmsp3-alpha. Mixed
genotypes of each marker were found in pvcs 1.3%, pvmsp1
0.7% and pvmsp3-alpha 8.6%. The overall rate of mixed
gene infection was 10.6% using all three genetic markers.
The most common alleles for each of the three genes were
seen in 31.7% of samples for pvcs (allele7-bVK210 no/in),
17% of samples for the second fragment of pvmsp1
(allele18-b a1 m1) and 14.5% for pvmsp3 (allele1-a a11
ha1) (Figure 2, 4, and 6). Therefore, when genetically
homogeneous parasite lines are considered in this area,
the three markers can distinguish a potential 14,245 (11 ×
35 × 37) unique genotypes. In the combination of three
genetic markers, The most common three marker geno-
type was b VK210 no/in, b a1 m1, c a1 h1 allele, which
occurred at a rate of 2% (n = 3/151).
Table 2: Size and RFLP patterns and frequency of pvmsp1 alleles detected (the second fragment) (n = 151).
Alleles Size variation Alu1 RFLP patterns Mnl1 RFLP patterns n (%)
1 a a1 m1 20 (13.2%)
2 a a1 m2 2 (1.32%)
3 a a2 m1 3 (2.0%)
4 a a2 m2 17 (11.2%)
5 a a2 m4 1 (0.66%)
6a a 2 m 5 1
7a a 3 m 1 1
8a a 3 m 6 1
9a a 4 m 1 1
10 a a4 m2 1
11 a a4 m4 1
12 a a5 m4 6 (4.0%)
13 a a5 m5 1
14 a a6 m4 2
15 a a6 m5 13 (8.6%)
16 a a7 m4 1
17 a a7 m5 1
18 b a1 m1 26 (17.3%)
19 b a1 m2 5 (3.3%)
20 b a2 m1 1
21 b a2 m2 7 (4.6%)
22 b a3 m1 1
23 b a3 m2 1
24 b a3 m5 1
25 b a4 m1 2
26 b a5 m1 1
27 b a5 m2 2
28 b a5 m4 16 (10.3%)
29 b a6 m1 1
30 b a6 m2 2
31 b a6 m4 4 (2.64%)
32 b a6 m5 2
33 b a7 m4 1
34 b a7 m6 4
35 b a8 m5 1
The allele frequency distribution of the second fragment of  pvmsp1 locus in the 151 Kolkata isolates characterized by a  combination of fragment size and sequence type using RFLP Figure 4
The allele frequency distribution of the second fragment of 
pvmsp1 locus in the 151 Kolkata isolates characterized by a 
combination of fragment size and sequence type using RFLP.Malaria Journal 2006, 5:71 http://www.malariajournal.com/content/5/1/71
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Discussion
The results showed that P. vivax parasites from Kolkata
demonstrated an extremely high prevalence of VK210
type in the pvcs gene (with only one VK247 type), high
polymorphism in both merozoite surface proteins
(pvmsp1 and pvmsp3 alpha), and low rates (10.6%) of
multiple genotype infection.
The predominance in Kolkata isolates of VK210 pvcs gene
type (99.3%) has not been seen elsewhere to the same
extent. Recent studies in Thailand have found rates of
70.5% [35], 78% [24] and 90% [28], though these results
were in sharp contrast to those of earlier studies in which
VK247 was found to be the predominant type; 83% in
Thai and 90% in Papua New Guinea samples by PCR/
Oligo Probe [23]. Another study of Indian strains has
shown the VK210 type to be predominant, but also dem-
onstrated (using a different technique) significant num-
bers of VK247 type [33]. This phenomenon may be
attributed to selection by host immune pressure on a par-
ticular genotype, and/or the preferential production of
sporozoites carrying a specific variant [18], such as VK210
for pvcs in a mosquito species. These differences may also
be due to sampling biases or regional temporal fluctua-
tions of individual genotypes frequencies. The frequency
of absence of the pre-repeat insertion of VK210 in the pvcs
gene was 4.7% (7/150) and that of the post-repeat region
of the gene 56% (84/150) in Kolkata. In the absence of a
multicentre study involving various regions of India it is
difficult to define the extent to which the observed differ-
ence was in any way related to the functional aspects of
the Kolkata strain.
In this study, two major types of the pvmsp1 marker con-
taining 35 alleles were found. A similar degree of diversity
(36 allelic types) was also found in the study from Thai-
land using the same laboratory protocol [28], and with a
different protocol in Papua New Guinea and Indian
strains [16,42]. For pvmsp3-alpha, the present study
reveals 37 alleles with three size variants cut by two restric-
tion enzymes. The frequencies of the three pvmsp3-alpha
types were consistent with those found in Papua New
Guinea and Thailand [18,19]. A recent study using a dif-
ferent protocol revealed 16 size and sequence polymor-
phic allele in Indian strains [37]. This high degree of
polymorphism in the merozoite surface protein (pvmsp1
and pvmsp3-alpha) is similar to that found in other studies
from other regions.
All three markers show marked genetic diversity in Kolk-
ata strains, with 11 alleles for pvcs, 35 alleles for the sec-
ond fragment of pvmsp1, and 37 alleles for pvmsp3-alpha.
This compares with another study of Indian vivax isolates
which revealed 2 sequence variants of pvcs, 9 size variants
in pvgam1, and 16 size variants with sequence polymor-
phism in pvmsp3-alpha gene [37].
The frequency of multiple genotype infections of P. vivax
malaria has been estimated in many regions but it is diffi-
cult to compare these values due to differences in sam-
pling and genotyping methods. The proportion of mixed
gene infections estimated in Papua New Guinea, India,
and Thailand ranges from 30% to 65% [16,20,24,25]. The
Frequency distribution of alleles at the pvmsp3-alpha loci  observed in the 151 Kolkata isolates Figure 6
Frequency distribution of alleles at the pvmsp3-alpha loci 
observed in the 151 Kolkata isolates.
Three sizes of pvmsp3-alpha gene product in the 151 Kolkata  isolates Figure 5
Three sizes of pvmsp3-alpha gene product in the 151 Kolkata 
isolates. The three sizes a, b and c represented are 1900, 
1500 and 1100 bp, respectively. M is a 100 bp DNA ladder 
marker and M is a 1 kb DNA ladder. Double bands reflect 
infection with multiple genotypes.Malaria Journal 2006, 5:71 http://www.malariajournal.com/content/5/1/71
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present study with a relatively large sampling size, shows
an overall 10.6% for multiple genotypes (1.3% for pvcs,
0.7% for pvmsp1 and 8.6% for pvmsp3 alpha). This rate
may reflect a limitation in the sensitivity of PCR for the
detection of multiple genotype infections, despite the
high degree of polymorphism seen.
According to the Calcutta School of Tropical Medicine
Report 2005, the malaria clinic treats around 6,000
malaria positive cases annually, of which an average of
65% are caused by P. vivax. The rate of mixed infection
with both P. vivax and P. falciparum during the last few
years has declined (1.0% in 1997, 0.7% in 1998 and 0.1%
in 2001) [6]. The samples from Kolkata were collected
from an urban area where vivax malaria remains chloro-
quine-sensitive, but where recurrences are frequent. Only
a few cases were contracted outside of central Kolkata. The
high degree of polymorphism and low level of multiple
genotype infection probably reflects the nature of this
endemic setting. More study is needed to assess whether
these discrepancies reflect true differences between dis-
ease populations, or are due to differences in sample sizes
or the laboratory methodology [20,38].
Conclusion
When genotyped using three polymorphic markers (pvcs,
pvmsp1 and pvmsp3-alpha)P. vivax infections in Kolkata
demonstrate a low rate of multiple genotype infection
despite a high degree of genetic diversity. Given the degree
of diversity found genotyping methods such as these are
Table 3: Size and RFLP patterns and frequency of pvmsp3-alpha alleles detected (n = 151).
Alleles Size variation Alu 1 RFLP patterns Hha1 RFLP patterns n (%)
1 a al 1 h1 22 (14.5%)
2a a l  1 h 2 3
3a a l  1 h 3 3
4a a l  1 h 4 5  ( 3 . 3 % )
5a a l  2 h 1 2
6a a l  2 h 2 4
7a a l  2 h 3 3
8a a l  2 h 4 2
9a a l  3 h 1 8  ( 5 . 2 % )
10 a al 3 h2 2
11 a al 3 h3 13 (8.6%)
12 a al 3 h4 10 (6.6%)
13 a al 3 h5 2
14 a al 4 h1 2
15 a al 4 h3 5
16 a al 4 h4 5
17 a al 4 h5 1
18 a al 5 h3 8 (5.2%)
19 a al 5 h4 1
20 a al 5 h5 1
21 b al 1 h1 3
22 b al 1 h2 5
23 b al 1 h3 1
24 b al 2 h1 2
25 b al 2 h2 3
26 b al 3 h1 1
27 b al 3 h3 3
28 b al 4 h4 1
29 c al 1 h1 11 (7.2%)
30 c al 1 h2 6 (4.0%)
31 c al 1 h4 1
32 c al 2 h2 3
33 c al 3 h1 1
34 c al 3 h3 5
35 c al 3 h5 1
36 c al 4 h3 1
37 c al 4 h4 1Malaria Journal 2006, 5:71 http://www.malariajournal.com/content/5/1/71
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likely to be of value in distinguishing relapse/recurrence
from reinfection in clinical trials of antimalarial drug effi-
cacy.
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